StockNews.AI
CNTX
StockNews.AI
146 days

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

1. CNTX to present CT-95 data at AACR Annual Meeting 2025. 2. CT-95 targets mesothelin in solid tumors, showing promising first-in-human dose. 3. Presentation scheduled for April 28, 2025, to discuss biological safety of CT-95.

6m saved
Insight
Article

FAQ

Why Bullish?

The upcoming presentation indicates promising clinical progress, historically linked to price increases.

How important is it?

The data presentation suggests significant advancements for CT-95, which could attract investor interest.

Why Short Term?

The effect will likely be felt soon after the presentation, akin to previous product announcements.

Related Companies

CRMDIMMPSGEN
March 26, 2025 16:02 ET  | Source: Context Therapeutics Inc. PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster regarding the Company’s clinical asset, CT-95, a mesothelin (“MSLN”) x CD3 TCE will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. Context will present data highlighting the selection of the first-in-human dose of CT-95, using the minimal anticipated biological effect level (“MABEL”) approach, as required for immune agonist drugs. This is the dose level expected to lead to a minimal biological effect level in humans. The weight of evidence of these data supports the safety of the proposed clinical starting dose of 0.1 μg/kg for CT-95. Poster Presentation Details: Title: Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelinAbstract Number:  2139Date and Time: Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. CTSession Category: Clinical ResearchSession: PO.CL06.04 - Therapeutic Antibodies, Including Engineered Antibodies 1Location: Poster Section 34 For more information and to view the Company’s abstract, visit the AACR Annual Meeting website. About CT-95CT-95 is a MSLN x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. One challenge in developing MSLN-targeted therapies has been the presence of MSLN fragments, also referred to as shed or soluble MSLN, found in both blood and the tumor microenvironment that can serve as a decoy or sink for MSLN-targeting antibodies. CT-95 is a fully humanized bispecific T cell engager that has a moderate affinity but high avidity for membrane-bound MSLN, that is intended to minimize the impact of the shed MSLN. About Context Therapeutics®Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn. Forward-looking StatementsThis press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company, its employees and certain AACR presenters to participate in and present at conferences, (ii) our expectation that the dose level will lead to a minimal biological effect level in humans, (iii) the potential benefits, characteristics, safety and side effect profile of our product candidates, and (iv) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise. Investor Relations Contact:Jennifer MinaiChief Financial OfficerContext Therapeutics Inc.IR@contexttherapeutics.com

Related News